COMPANY PROFILE // THE 014 REPORT
Akari Therapeutics Plc
AKTX (Nasdaq) · Formerly: Celsus Therapeutics Plc.; Morria Biopharmaceuticals PLC
Assembled from 2 government sources in 2.5 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberNT 10-Q filed on 2026-05-18: notice that a periodic report would be late (2 such notices in 24 months).
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-11-26 (last 24 months).
- InfoRegistered business address (401 EAST JACKSON STREET, TAMPA) is shared with 15 other entities in our records (SEC registrants and IRS-registered organizations).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record; address shared with 15 entities.
Akari Therapeutics Plc is an SEC-registered operating company in pharmaceutical preparations, incorporated in United Kingdom, based in Tampa, FL; listed as AKTX (Nasdaq).[source] It has filed 76 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-19.[source] Its largest institutional holders on 13F filings are MMCAP International Inc. SPC, Cresset Asset Management, LLC, JANE STREET GROUP, LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; NT 10-Q filed on 2026-05-18.[source]
- red0
- amber2
- info1
- MMCAP International Inc. SPC$1.0M
- Cresset Asset Management, LLC$211K
- JANE STREET GROUP, LLC$158K
- IFP Advisors, Inc$2K
- SBI Securities Co., Ltd.$143
- HRT FINANCIAL LP$140
- Caitong International Asset Management Co., Ltd$82
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO$72
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Farag Kameel D. · Interim CFO (Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Gaslightwala Abizer · CEO (Director,Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Bazemore Robert B · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- Huh Hoyoung · Director,10% owner · latest Form 4 2025-12-18 · filing · LinkedIn search
- Neal James R · Director · latest Form 4 2026-03-16 · filing · LinkedIn search
- Patel Samir Rashmikant · Director,10% owner · latest Form 4 2025-12-18 · filing · LinkedIn search
- Patel Sandip I · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- Prudo-Chlebosz Raymond · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001541157 | source |
| EIN | 98-1034922 | source |
| NY DOS ID | 4205807 | record |
| Business address (SEC) | 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602 | source |
Does not exist in the records we hold: LEI, UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (16)
- GENERATION INCOME PROPERTIES, INC. · SEC registrant
- REDEFINING REFUGE INC · IRS-registered organization
- AWAKENING MEDICAL RETREAT INC · IRS-registered organization
- MOJOS HOUSE · IRS-registered organization
- BACK 2 THE BEGINNING PROJECT INC · IRS-registered organization
- SCHIFINO FAMILY FOUNDATION INC · IRS-registered organization
- SHE REIGNS LEGACY INSTITUTE INC · IRS-registered organization
- TAMPA TICKETS JUST FOR KIDS INC · IRS-registered organization
- TAMPA BAY AREA COMMITTEE ON FOREIGN RELATIONS INC · IRS-registered organization
- AGRICULTURE SCIENCE EDUCATION AND TECHNOLOGIES CORPORATION · IRS-registered organization
- HELLO MS CEO EMPOWERMENT INC · IRS-registered organization
- HEY MY CHILD TEEN SUMMIT · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- ARDELYX, INC. · Bazemore Robert B
- AtlasClear Holdings, Inc. · Patel Sandip I
- BIOVIE INC. · Farag Kameel D.
- Nuvation Bio Inc. · Bazemore Robert B
- PLIANT THERAPEUTICS, INC. · Huh Hoyoung
- Processa Pharmaceuticals, Inc. · Neal James R
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-30 filing S-8 · SEC EDGAR
- 2026-10-30 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-10-01 filing Proxy statement · SEC EDGAR
- 2026-10-01 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-08-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-13 filing EFFECT · SEC EDGAR
- 2026-07-10 filing S-3/A · SEC EDGAR
- 2026-07-08 filing S-3/A · SEC EDGAR
- 2026-07-07 filing EFFECT · SEC EDGAR
- 2026-07-02 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-07-02 filing S-3 · SEC EDGAR
- 2026-06-26 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-06-26 filing S-1/A · SEC EDGAR
- 2026-06-04 filing Proxy statement · SEC EDGAR
- 2026-06-03 filing D · SEC EDGAR
- 2026-05-22 filing PRE 14A · SEC EDGAR
- 2026-05-22 filing 8-K items 1.01,3.02,9.01 · SEC EDGAR
- 2026-05-21 filing RW · SEC EDGAR
- 2026-05-19 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-18 filing NT 10-Q · SEC EDGAR
- 2026-05-08 filing Registration (S-1) · SEC EDGAR
- 2026-04-15 filing EFFECT · SEC EDGAR
- 2026-04-10 filing POS AM · SEC EDGAR
- 2026-04-02 filing DRS · SEC EDGAR
- 2026-03-31 filing F-6/A · SEC EDGAR
- 2026-03-30 filing Annual report (10-K) · SEC EDGAR
- 2026-03-17 filing 8-K items 3.03,7.01,9.01 · SEC EDGAR
170 earlier entries
- 2026-03-16 insider First Form 3/4/5 on record for Neal James R (Director)
- 2026-03-04 filing SCHEDULE 13D/A
- 2026-03-04 filing SCHEDULE 13D/A
- 2026-03-02 filing 8-K items 5.07
- 2026-02-02 filing Proxy statement
- 2026-01-29 filing EFFECT
- 2026-01-27 filing UPLOAD
- 2026-01-27 filing CORRESP
- 2026-01-23 filing Registration (S-1)
- 2026-01-22 filing PRE 14A
- 2025-12-18 insider First Form 3/4/5 on record for Bazemore Robert B (Director)
- 2025-12-18 insider First Form 3/4/5 on record for Huh Hoyoung (Director,10% owner)
- 2025-12-18 insider First Form 3/4/5 on record for Patel Samir Rashmikant (Director,10% owner)
- 2025-12-18 insider First Form 3/4/5 on record for Prudo-Chlebosz Raymond (Director)
- 2025-12-17 filing 8-K items 1.01,1.02,3.02,7.01,9.01
- 2025-12-17 filing 424B5
- 2025-12-16 filing 8-K items 5.07,9.01
- 2025-12-08 filing 8-K items 7.01,9.01
- 2025-12-05 filing 424B3
- 2025-12-02 filing EFFECT
- 2025-12-01 filing CORRESP
- 2025-11-26 filing 8-K items 3.01
- 2025-11-17 filing Proxy statement
- 2025-11-17 filing Registration (S-1)
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-11-07 filing PRE 14A
- 2025-10-24 filing D
- 2025-10-24 insider First Form 3/4/5 on record for Farag Kameel D. (Interim CFO)
- 2025-10-23 officer change 8-K items 5.02,9.01
- 2025-10-16 filing 8-K items 1.01,3.02,9.01
- 2025-10-16 filing 424B5
- 2025-10-15 filing 8-K items 7.01,9.01
- 2025-09-29 filing 8-K items 8.01
- 2025-09-25 filing 8-K items 1.01,8.01,9.01
- 2025-08-29 filing Registration (S-1)
- 2025-08-29 officer change 8-K items 1.01,3.02,5.02,9.01
- 2025-08-21 filing 8-K items 1.01,1.02,2.03,9.01
- 2025-08-19 filing 8-K items 7.01,9.01
- 2025-08-13 filing Quarterly report (10-Q)
- 2025-07-31 filing EFFECT
- 2025-07-30 filing CORRESP
- 2025-07-30 filing UPLOAD
- 2025-07-29 filing S-8
- 2025-07-29 filing S-3
- 2025-07-01 officer change 8-K items 5.02,5.07,9.01
- 2025-06-12 insider First Form 3/4/5 on record for Gaslightwala Abizer (CEO)
- 2025-06-06 filing ARS
- 2025-06-06 filing Proxy statement
- 2025-05-23 filing PRE 14A
- 2025-05-15 filing 8-K items 2.02,9.01
- 2025-05-14 filing EFFECT
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-14 filing 424B3
- 2025-05-12 filing CORRESP
- 2025-05-09 filing UPLOAD
- 2025-05-06 filing S-3
- 2025-04-29 insider First Form 3/4/5 on record for Patel Sandip I (Director)
- 2025-04-16 filing 8-K items 2.02,9.01
- 2025-04-15 filing Annual report (10-K)
- 2025-03-31 filing NT 10-K
- 2025-03-20 officer change 8-K items 5.02,9.01
- 2025-03-03 filing 8-K items 1.01,3.02,9.01
- 2025-02-14 filing SCHEDULE 13D/A
- 2025-01-13 filing 8-K items 7.01
- 2024-12-18 officer change 8-K items 5.02
- 2024-12-16 officer change 8-K items 5.02
- 2024-12-12 officer change 8-K items 5.02
- 2024-12-06 filing SC 13D/A
- 2024-11-19 filing Quarterly report (10-Q)
- 2024-11-15 filing NT 10-Q
- 2024-11-14 officer change 8-K items 1.01,2.01,3.01,3.02,5.02,7.01,9.01
- 2024-11-08 filing 8-K items 5.07,7.01,9.01
- 2024-10-15 filing 425
- 2024-10-11 filing EFFECT
- 2024-10-11 filing 424B3
- 2024-10-09 filing CORRESP
- 2024-10-09 filing S-4/A
- 2024-10-04 filing 8-K items 3.01
- 2024-09-30 filing CORRESP
- 2024-09-30 filing S-4/A
- 2024-09-26 filing UPLOAD
- 2024-09-18 officer change 8-K items 5.02,8.01,9.01
- 2024-09-16 filing 424B5
- 2024-09-13 filing EFFECT
- 2024-09-13 filing S-4
- 2024-09-11 filing CORRESP
- 2024-09-11 filing UPLOAD
- 2024-09-06 filing S-3
- 2024-09-06 filing 8-K items 8.01,9.01
- 2024-08-23 officer change 8-K/A items 5.02
- 2024-08-19 filing Quarterly report (10-Q)
- 2024-08-19 filing 8-K items 2.02,9.01
- 2024-08-15 filing NT 10-Q
- 2024-07-01 filing 8-K items 5.07
- 2024-06-20 filing SC 13D/A
- 2024-06-18 filing SC 13D
- 2024-06-07 filing SC 13D
- 2024-06-05 officer change 8-K items 5.02,9.01
- 2024-06-04 filing 425
- 2024-06-04 filing 8-K items 1.01,3.02,9.01
- 2024-06-04 filing ARS
- 2024-06-03 filing Proxy statement
- 2024-05-16 filing 8-K items 2.02,9.01
- 2024-05-15 filing Quarterly report (10-Q)
- 2024-05-07 officer change 8-K items 2.05,5.02
- 2024-05-01 filing 425
- 2024-05-01 officer change 8-K items 5.02,8.01,9.01
- 2024-04-11 filing 8-K items 3.01
- 2024-04-01 filing 8-K items 2.02,9.01
- 2024-03-29 filing Annual report (10-K)
- 2024-03-11 filing 425
- 2024-03-11 filing 8-K items 1.01,3.02,9.01
- 2024-03-05 filing 425
- 2024-03-05 filing 425
- 2024-03-05 filing 8-K items 1.01,7.01,9.01
- 2024-01-09 filing D
- 2024-01-04 filing SC 13D/A
- 2024-01-02 filing 8-K items 1.01,3.02,7.01,8.01,9.01
- 2023-12-01 filing 6-K
- 2023-11-16 filing 6-K
- 2023-10-27 filing 424B3
- 2023-10-26 filing EFFECT
- 2023-10-25 filing CORRESP
- 2023-10-24 filing UPLOAD
- 2023-10-23 filing EFFECT
- 2023-10-23 filing EFFECT
- 2023-10-20 filing SC 13D/A
- 2023-10-20 filing POS AM
- 2023-10-20 filing POS AM
- 2023-10-20 filing F-3
- 2023-10-19 filing D
- 2023-10-12 filing S-8
- 2023-09-29 filing 6-K
- 2023-09-21 filing 6-K
- 2023-09-05 filing 6-K
- 2023-08-18 filing 6-K
- 2023-08-17 filing F-6 POS
- 2023-08-15 filing 6-K
- 2023-08-02 filing 6-K
- 2023-07-27 filing 6-K
- 2023-07-25 filing 6-K
- 2023-07-19 filing 6-K
- 2023-07-13 filing 6-K
- 2023-07-11 filing 6-K
- 2023-07-07 filing 6-K
- 2023-07-06 filing 6-K
- 2023-07-05 filing 6-K
- 2023-06-30 filing 6-K
- 2023-06-06 filing EFFECT
- 2023-06-06 filing EFFECT
- 2023-06-06 filing 6-K
- 2023-05-31 filing POS AM
- 2023-05-31 filing POS AM
- 2023-05-31 filing S-8
- 2023-05-22 filing 6-K
- 2023-05-05 filing 6-K
- 2023-05-03 filing 6-K
- 2023-05-01 filing 6-K
- 2023-05-01 filing Annual report (20-F)
- 2023-04-25 filing 6-K
- 2023-04-14 filing SC 13D/A
- 2023-03-31 filing 6-K
- 2023-03-31 filing 424B5
- 2023-03-29 filing 6-K
- 2023-03-28 filing 6-K
- 2023-03-13 filing 6-K
- 2023-02-21 filing 6-K
- 2023-02-15 filing 6-K
- 2023-02-15 filing 6-K
- 2023-02-13 filing 6-K
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-12 (within 30 days) 10-Q filed
- 2026-10-30 (within 30 days) S-8 filed
- 2026-10-30 (within 30 days) 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-10-01 (older) DEF 14A filed
- 2026-10-01 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-13 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-13 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:AKTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1541157 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | AKTX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 981034922 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001541157 | SEC EDGAR / IRS |
| CUSIP | 00972G405 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001541157 | SEC EDGAR |
former name (shown apart, not merged) (2)
- former nameCelsus Therapeutics PLC · ClinicalTrials.gov
- former nameMorria Biopharmaceuticals PLC · ClinicalTrials.gov
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$17,298,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 10:06 UTC | Report an error |
| Total assets (at 2025-12-31) | $47,892,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 10:06 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $28,328,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 10:06 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 10:06 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
| State of incorporation | X0 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
| Business address | 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 10:06 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$10,568,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 10:06 UTC | Report an error |
| Form D total offering amount (D filed 2026-06-03) | $5,500,000 | 2026-06-03 | D | as filed | 2026-11-22 10:06 UTC | Report an error |
| Form D total amount sold (D filed 2026-06-03) | $1,833,333 | 2026-06-03 | D | as filed | 2026-11-22 10:06 UTC | Report an error |
| Form D industry group | Other Health Care | 2026-06-03 | D | as filed | 2026-11-22 10:06 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-06-03 | D | as filed | 2026-11-22 10:06 UTC | Report an error |
| Form D date of first sale | 2026-05-20 | 2026-06-03 | D | as filed | 2026-11-22 10:06 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001493152-26-051372
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$4,843,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001493152-26-051372 | 2026-11-22 10:06 UTC | Report an error |
| Interest expense | $85,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001493152-26-051372 | 2026-11-22 10:06 UTC | Report an error |
| Cash and cash equivalents | $5,743,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001493152-26-051372 | 2026-11-22 10:06 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-12 Filing 10-Q filed
- 2026-10-30 Filing S-8 filed
- 2026-10-30 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-10-01 Filing DEF 14A filed
- 2026-10-01 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-13 Filing 10-Q filed
- 2026-07-13 Filing EFFECT filed
- 2026-07-10 Filing S-3/A filed
- 2026-07-08 Filing S-3/A filed
- 2026-07-07 Filing EFFECT filed
- 2026-07-02 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-07-02 Filing S-3 filed
- 2026-06-26 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-06-26 Filing S-1/A filed
- 2026-06-04 Filing DEF 14A filed
- 2026-06-03 Filing D filed
- 2026-05-22 Filing PRE 14A filed
- 2026-05-22 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-05-21 Filing RW filed
- 2026-05-19 Filing 10-Q filed
- 2026-05-18 Filing NT 10-Q filed
- 2026-05-08 Filing S-1 filed
- 2026-04-15 Filing EFFECT filed
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | MMCAP International Inc. SPC | $1,024,500 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 2 | Cresset Asset Management, LLC | $210,647 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 3 | JANE STREET GROUP, LLC | $158,418 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 4 | IFP Advisors, Inc | $1,854 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 5 | SBI Securities Co., Ltd. | $143 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 6 | HRT FINANCIAL LP | $140 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 7 | Caitong International Asset Management Co., Ltd | $82 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 8 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $72 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
| 9 | Truvestments Capital LLC | $10 | 2026-06-30 | SEC 13F filing | 2026-11-22 10:06 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
4 state and city records carry this company's exact name, from 3 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAKARI THERAPEUTICS PLC · exact legal name · sx:elic:ctcred:2039304 Compare
- possible matchAKARI THERAPEUTICS PLC · exact legal name · sx:elic:ctcred:1781517 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAKARI Therapeutics · name equals 'Akari Therapeutics' but other unrelated entities share it · sx:ctgov:h1a24d2caf1d7b78c Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAKARI THERAPEUTICS, PLC · exact legal name · sx:nydos:4205807 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1541157.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001541157. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.